Melanie Cornpropst

1.3k total citations
27 papers, 467 citations indexed

About

Melanie Cornpropst is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Melanie Cornpropst has authored 27 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 6 papers in Epidemiology and 6 papers in Immunology. Recurrent topics in Melanie Cornpropst's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (14 papers), Hepatitis C virus research (6 papers) and Complement system in diseases (4 papers). Melanie Cornpropst is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (14 papers), Hepatitis C virus research (6 papers) and Complement system in diseases (4 papers). Melanie Cornpropst collaborates with scholars based in United Kingdom, United States and Italy. Melanie Cornpropst's co-authors include William T. Symonds, M. Michelle Berrey, Jill Denning, M. Rodríguez‐Torres, John G. McHutchison, Eric Lawitz, Efsevia Albanis, Franck Rousseau, Vlad Ratziu and Wei Liang and has published in prestigious journals such as Blood, Hepatology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Melanie Cornpropst

25 papers receiving 448 citations

Peers

Countries citing papers authored by Melanie Cornpropst

Since Specialization

Citations

This map shows the geographic impact of Melanie Cornpropst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melanie Cornpropst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melanie Cornpropst more than expected).

Fields of papers citing papers by Melanie Cornpropst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melanie Cornpropst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melanie Cornpropst. The network helps show where Melanie Cornpropst may publish in the future.

Co-authorship network of co-authors of Melanie Cornpropst

This figure shows the co-authorship network connecting the top 25 collaborators of Melanie Cornpropst. A scholar is included among the top collaborators of Melanie Cornpropst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melanie Cornpropst. Melanie Cornpropst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS 2022 ·HemaSphere ·Austin Kulasekararaj, Wolfgang Füreder, Andrew McDonald, (unknown), (unknown), David Collins, Melanie Cornpropst, Sylvia Dobo, (unknown), (unknown), William Sheridan, Morag Griffin, Antonio M. Risitano	5
2	Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema 2022 ·Clinical and Translational Science ·Amanda Mathis, Mark Sale, Melanie Cornpropst, William Sheridan, (unknown)	5
3	P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS 2022 ·HemaSphere ·Andrew McDonald, (unknown), Austin Kulasekararaj, Wolfgang Füreder, Morag Griffin, Melanie Cornpropst, (unknown), (unknown), David Collins, William Sheridan, Antonio M. Risitano	4
4	P048 IMPROVED PATIENT SATISFACTION WITH BEROTRALSTAT IN PATIENTS SWITCHING FROM INJECTABLE HEREDITARY ANGIOEDEMA (HAE) PROPHYLACTIC TREATMENTS 2021 ·Annals of Allergy Asthma & Immunology ·Jonine L. Bernstein, (unknown), Dianne Tomita, Melanie Cornpropst, James L. Sublett	3
5	BCX9930, an Oral Factor D Inhibitor, for the Potential Treatment of Alternative Pathway Mediated Diseases: Interim Results of a Phase 1 Study in Healthy Subjects 2020 ·Blood ·(unknown), Amanda Mathis, Stuart Mair, Diane Gesty‐Palmer, Melanie Cornpropst, William Sheridan, Xilin Chen, David S. Reynolds, Cynthia Parker, Y.S. Babu	3
6	BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 2020 ·Blood ·Austin Kulasekararaj, (unknown), Andrew McDonald, Melanie Cornpropst, Phil Collis, (unknown), (unknown), (unknown), Diane Gesty‐Palmer, William Sheridan, Antonio M. Risitano	4
7	P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY 2019 ·Annals of Allergy Asthma & Immunology ·Marc A. Riedl, William R. Lumry, Aleena Banerji, Emel Aygören‐Pürsün, Jonine L. Bernstein, Marcus Maurer, Marco Cicardi, (unknown), Bruce L. Zuraw, Sylvia Dobo, Melanie Cornpropst, Heather A. Iocca, Emese Nagy, Sonya R Murray, P. Collis, William Sheridan, D. Johnston	3
8	ORAL ADMINISTRATION OF A LIQUID FORMULATION OF BCX7353 RAPIDLY PROVIDES SUSTAINED CONCENTRATIONS AND KALLIKREIN INHIBITION 2018 ·Annals of Allergy Asthma & Immunology ·(unknown), (unknown), Melanie Cornpropst, William Sheridan, Emel Aygören‐Pürsün	1
9	RELATIONSHIP OF TARGET CONCENTRATIONS WITH EFFICACY: RESULTS FROM THE APEX-1 STUDY OF BCX7353 2018 ·Annals of Allergy Asthma & Immunology ·Henriette Farkas, Emel Aygören‐Pürsün, (unknown), Aarnoud Huissoon, Tamar Kinaciyan, (unknown), Melanie Cornpropst, William Sheridan, Marcus Maurer, Marco Cicardi	1
10	BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects 2016 ·Journal of Allergy and Clinical Immunology ·Melanie Cornpropst, Sylvia Dobo, (unknown), Angela M. Rose, (unknown), Y.S. Babu, Phil Collis, William Sheridan	5
11	Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study 2016 ·Allergy ·Melanie Cornpropst, P. Collis, (unknown), Y.S. Babu, (unknown), (unknown), Lei Fang, Jian Zong, William Sheridan	9
12	Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE) 2015 ·Journal of Allergy and Clinical Immunology ·Emel Aygören‐Pürsün, Markus Magerl, Jochen Graff, Inmaculada Martinez‐Saguer, W. Kreuz, Hilary Longhurst, Iman Nasr, Murat Baş, Ulrich Straßen, Jian Zong, Fang Lei, Melanie Cornpropst, Sylvia Dobo, Phil Collis, William Sheridan, Marcus Maurer	4
13	A Simple, Sensitive and Selective Fluorogenic Assay To Monitor Plasma Kallikrein Inhibitory Activity Of BCX4161 In Activated Plasma 2014 ·Journal of Allergy and Clinical Immunology ·Y.S. Babu, (unknown), Jianwen Zhang, Melanie Cornpropst, Phil Collis, William Sheridan	4
14	All‐oral therapy with nucleotide inhibitors sofosbuvir and GS‐0938 for 14 days in treatment‐naive genotype 1 hepatitis C (NUCLEAR) 2013 ·Journal of Viral Hepatitis ·Eric Lawitz, M. Rodríguez‐Torres, Jill Denning, Anita Mathias, (unknown), Bing Gao, Melanie Cornpropst, M. Michelle Berrey, William T. Symonds	24
15	Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial 2012 ·Journal of Hepatology ·M. Rodríguez‐Torres, Eric Lawitz, Kris V. Kowdley, David R. Nelson, Edwin DeJesus, John G. McHutchison, Melanie Cornpropst, Michael Mader, Efsevia Albanis, Deyuan Jiang, Christy M. Hebner, William T. Symonds, M. Michelle Berrey, Jay Lalezari	85
16	1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977 2012 ·Journal of Hepatology ·Melanie Cornpropst, (unknown), (unknown), (unknown), Harry Alcorn, (unknown), Michèle M. Sale, Liang Fang, M. Michelle Berrey, William T. Symonds	62
17	1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS 2012 ·Journal of Hepatology ·E. Läwitz, M. Rodríguez‐Torres, Melanie Cornpropst, Jill Denning, (unknown), Lindsay McNair, (unknown), M. Michelle Berrey, William T. Symonds	29
18	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis 2011 ·Hepatology ·Vlad Ratziu, Muhammad Y. Sheikh, Arun J. Sanyal, Joseph K. Lim, Hari S. Conjeevaram, Naga Chalasani, Manal F. Abdelmalek, (unknown), Christophe Renou, Melissa Palmer, Robert A. Levine, Raj Bhandari, Melanie Cornpropst, Wei Liang, Benjamin King, Elsa Mondou, Franck Rousseau, John G. McHutchison, Mario Chojkier	134
19	273 SHORT TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH CHRONIC HCV INFECTION 2010 ·Journal of Hepatology ·M.P. Manns, Eric Lawitz, A. I. M. Hoepelman, Hongjo Choi, (unknown), Melanie Cornpropst, Wen‐Chen Liang, Bernard D. King, Kenneth Hirsch, David Oldach, Franck Rousseau	10
20	84 SAFETY, TOLERABILITY AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) 2010 ·Journal of Hepatology ·Vlad Ratziu, Mario Chojkier, (unknown), A. Sanyal, Joseph K. Lim, Hari S. Conjeevaram, Naga Chalasani, Manal F. Abdelmalek, A. Bakken, Christophe Renou, Melissa Palmer, R Levine, (unknown), Melanie Cornpropst, Wen Liang, Barbara King, Elsa Mondou, Franck Rousseau	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact